New russian drug fluorothiazinone enters first human safety tests
NCT ID NCT07184606
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial will test the safety of a new drug called fluorothiazinone in 70 healthy adults aged 18 to 45. Participants will receive either a single dose or a short course of the drug or a placebo. The main goal is to check for side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fluorothiazinone
- What this could lead to
- If safe, this could lead to further studies testing fluorothiazinone for treating infections or other conditions.
- What could go wrong
- This is a very early Phase 1 safety trial in only 70 healthy people. It cannot prove the drug works for any disease, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.